2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. Ribosomal S6 Kinase (RSK)

Ribosomal S6 Kinase (RSK)

S6K

Ribosomal S6 Kinase (RSK)

Related Products

PDF 0.51 MB

Ribosomal S6 Kinase (RSK) is a family of serine/threonine protein kinases involved in the regulation of cell viability. RSK is phosphorylated in response to mitogens by activation of one or more protein kinase cascades. Phosphorylation of S6 in vivo is catalyzed by (at least) two distinct mitogen-activated S6 kinase families distinguishable by size, the 70 kDa and 90 kDa S6 kinases. Both S6 kinases are activated by serine/threonine phosphorylation.

The p90 ribosomal s6 kinase family (1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. They regulate diverse cellular processes, such as cell growth, cell motility, cell survival and cell proliferation. The p70 ribosomal protein S6 kinase, an important member of AGC family, is a kind of multifunctional Ser/Thr kinases, which plays an important role in mTOR signaling cascade. The p70 ribosomal protein S6 kinase is closely associated with diverse cellular processes such as protein synthesis, mRNA processing, glucose homeostasis, cell growth and apoptosis.

Ribosomal S6 Kinase (RSK) Isoform Specific Products:

Ribosomal S6 Kinase (RSK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156498
    RMC-7977
    		Inhibitor 99.48%
    RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models.
    RMC-7977
  • HY-10510
    BI-D1870
    		Inhibitor 99.72%
    BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC50s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively.
    BI-D1870
  • HY-15773
    PF-4708671
    		Inhibitor 99.85%
    PF-4708671 is a potent cell-permeable S6K1 inhibitor with a Ki of 20 nM and IC50 of 160 nM.
    PF-4708671
  • HY-N0643
    Carnosol
    		Inhibitor 99.90%
    Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC50 of ~5.5 μM. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1).
    Carnosol
  • HY-N0418
    Quercitrin
    		Inhibitor 99.72%
    Quercitrin (Quercetin 3-rhamnoside) is a bioflavonoid compound with potential anti-inflammation, antioxidative and neuroprotective effect. Quercitrin induces apoptosis of colon cancer cells. Quercitrin can be used for the research of cardiovascular and neurological disease research.
    Quercitrin
  • HY-132891A
    RSK4-IN-1 TFA
    		Inhibitor
    RSK4-IN-1 TFA is a potent RSK4 inhibitor with a IC50 value of 9.5 nM. RSK4-IN-1 TFA has antitumor activity.
    RSK4-IN-1 TFA
  • HY-N0643R
    Carnosol (Standard)
    		Inhibitor
    Carnosol (Standard) is the analytical standard of Carnosol. This product is intended for research and analytical applications. Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC50 of ~5.5 μM. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1).
    Carnosol (Standard)
  • HY-N0418R
    Quercitrin (Standard)
    		Inhibitor
    Quercitrin (Standard) is the analytical standard of Quercitrin. This product is intended for research and analytical applications. Quercitrin (Quercetin 3-rhamnoside) is a bioflavonoid compound with potential anti-inflammation, antioxidative and neuroprotective effect. Quercitrin induces apoptosis of colon cancer cells. Quercitrin can be used for the research of cardiovascular and neurological disease research.
    Quercitrin (Standard)
  • HY-12493A
    LY-2584702 tosylate salt
    		Inhibitor 98.58%
    LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
    LY-2584702 tosylate salt
  • HY-136848
    SM1-71
    		Inhibitor
    SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.
    SM1-71
  • HY-19712
    LJH685
    		Inhibitor 99.99%
    LJH685 is a potent, ATP-competitive and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC50s of 6, 5, 4 nM, respectively.
    LJH685
  • HY-B0167A
    Sodium Salicylate
    		Inhibitor 99.93%
    Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.
    Sodium Salicylate
  • HY-16071
    AT13148
    		Inhibitor 99.21%
    AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.
    AT13148
  • HY-19713
    LJI308
    		Inhibitor 99.07%
    LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC50s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.
    LJI308
  • HY-12059
    AT7867
    		Inhibitor 99.88%
    AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
    AT7867
  • HY-15237
    SL 0101-1
    		Inhibitor ≥98.0%
    SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC50 of 89 nM. SL 0101-1 (SL0101) is a selective RSK1/2 inhibitor, with a Ki of 1 μM.
    SL 0101-1
  • HY-100501
    M2698
    		Inhibitor 99.87%
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.
    M2698
  • HY-10579
    Pluripotin
    		Inhibitor 98.86%
    Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 μM, respectively.
    Pluripotin
  • HY-133028
    CKI-7 free base
    		Inhibitor 99.80%
    CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.
    CKI-7 free base
  • HY-52101A
    FMK
    		Inhibitor 99.45%
    FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.
    FMK
Cat. No. Product Name / Synonyms Application Reactivity
Ribosomal S6 Kinase (RSK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.